Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.46 |
| ▸ | MERTK | Q12866 | 4/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.40 |
| ▸ | GAS6 | Q14393 | 3/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22553618 | 1.00 | SYK (0.46) | SYKMERTKPDE4BNPC1RAB9A | |
| SCHEMBL31360665 | 0.87 | MEN1 (0.49) | SYKMERTKNPC1RAB9AALDH1A1 | |
| SCHEMBL2622287 | 0.87 | MEN1 (0.49) | SYKMERTKNPC1RAB9AALDH1A1 | |
| SCHEMBL15249748 | 0.84 | SYK (0.51) | SYKMERTKPDE4BPPARG | |
| SCHEMBL28672168 | 0.81 | SYK (0.47) | SYKMERTKPDE4B | |
| SCHEMBL21554053 | 0.81 | SYK (0.50) | SYKMERTKPDE4BPPARGFLT3 | |
| SCHEMBL15249749 | 0.81 | SYK (0.65) | SYK | |
| SCHEMBL26931042 | 0.80 | MERTK (0.57) | SYKMERTKPPARGFLT3TYRO3 | |
| SCHEMBL26931049 | 0.80 | MERTK (0.57) | SYKMERTKPPARGFLT3TYRO3 | |
| SCHEMBL1226594 | 0.80 | MEN1 (0.49) | SYKMERTKPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203594-B2 | Anti-proliferative agents for treating PAH | EDNRB, EDNRA, PAH | SYK 3397/4885MERTK 4262/4885PDE4B 352/4885 |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | EDNRB, EDNRA, PAH | SYK 3397/4885MERTK 4262/4885PDE4B 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.